Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: Results of the MATLOC study

Journal of Urology

Volumn 189, Issue 3, 2013, Pages 1110-1116

  Stewart, Grant D ^a   Van Neste, Leander ^c   Delvenne, Philippe ^d   Delrée, Paul ^e   Delga, Agnès ^d   McNeill, S Alan ^a   O'Donnell, Marie ^a   Clark, James ^c   Van Criekinge, Wim ^c   Bigley, Joseph ^c   Harrison, David J ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

^c MDxHealth   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e Institute of Pathology and Genetics Gosselies   (Belgium)

Author keywords

biopsy; epigenomics; methylation; prostate; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BELGIUM; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; EPIGENETIC ASSAY; FOLLOW UP; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; UNITED KINGDOM;

BIOPSY, NEEDLE; DNA, NEOPLASM; EPIGENOMICS; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84873722466     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.08.219     Document Type: Article

References (29)

1. R. Siegel, D. Naishadham, A. Jemal Cancer statistics, 2012 CA: Cancer J Clin 62 2012 10
2. B. Djavan, P. Mazal, A. Zlotta Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study Prostate 47 2001 111
3. B. Djavan, V. Ravery, A. Zlotta Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 2001 1679
4. R. Damiano, R. Autorino, S. Perdona Are extended biopsies really necessary to improve prostate cancer detection? Prostate Cancer Prostatic Dis 6 2003 250
5. C.K. Naughton, D.C. Miller, D.E. Mager A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection J Urol 164 2000 388
6. S. Park, K. Shinohara, G.D. Grossfeld Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy J Urol 165 2001 1409
7. E.A. Allen, H. Kahane, J.I. Epstein Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy Urology 52 1998 803
8. S. Loeb, H.B. Carter, S.I. Berndt Complications after prostate biopsy: data from SEER-Medicare J Urol 186 2011 1830
9. S. Loeb, S. van den Heuvel, X. Zhu Infectious complications and hospital admissions after prostate biopsy in a European randomized trial Eur Urol 61 2012 1110
10. D.A. Troyer, M.S. Lucia, A.P. de Bruine Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies Cancer Epidemiol Biomarkers Prev 18 2009 2717
11. S.V. Harden, Z. Guo, J.I. Epstein Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma J Urol 169 2003 1138
12. H. Chai, R.E. Brown Field effect in cancer-an update Ann Clin Lab Sci 39 2009 331
13. C. Jeronimo, R. Henrique, M.O. Hoque A quantitative promoter methylation profile of prostate cancer Clin Cancer Res 10 2004 8472
14. A. Agathanggelou, W.N. Cooper, F. Latif Role of the Ras-association domain family 1 tumor suppressor gene in human cancers Cancer Res 65 2005 3497
15. P.J. Bastian, J. Ellinger, A. Wellmann Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci Clin Cancer Res 11 2005 4097
16. C. Jeronimo, H. Usadel, R. Henrique Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma J Natl Cancer Inst 93 2001 1747
17. M. Zhou, Y. Tokumaru, D. Sidransky Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies J Urol 171 2004 2195
18. Y. Tokumaru, S.V. Harden, D.I. Sun Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma Clinical Cancer Res 10 2004 5518
19. M. Nakayama, M.L. Gonzalgo, S. Yegnasubramanian GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer J Cell Biochem 91 2004 540
20. L. Van Neste, J.G. Herman, G. Otto The Epigenetic promise for prostate cancer diagnosis Prostate 72 2012 1248
21. L. Nonn, V. Ananthanarayanan, P.H. Gann Evidence for field cancerization of the prostate Prostate 69 2009 1470
22. J. Mehrotra, S. Varde, H. Wang Quantitative, spatial resolution of the epigenetic field effect in prostate cancer Prostate 68 2008 152
23. J.A. Hanson, J.W. Gillespie, A. Grover Gene promoter methylation in prostate tumor-associated stromal cells J Natl Cancer Inst 98 2006 255
24. L. Van Neste, J. Bigley, A. Toll A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection BMC Urol 12 2012 16
25. J.L. Campos-Fernandes, L. Bastien, N. Nicolaiew Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy Eur Urol 55 2009 600
26. D.M. Steinberg, J. Fine, R. Chappell Sample size for positive and negative predictive value in diagnostic research using case-control designs Biostatistics 10 2009 94
27. B.J. Trock, M.J. Brotzman, L.A. Mangold Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies BJU Int 110 2012 56
28. R.J. Ablin A retrospective and prospective overview of prostate-specific antigen J Cancer Res Clin Oncol 123 1997 583
29. R.R. Goode, S.J. Marshall, M. Duff Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients Prostate 73 2012 48